Intrinsic Imaging Awarded International Four Year Phase II Trial for New Treatment of Arthritis

Share Article

Intrinsic Imaging, an FDA audited, ISO 9001, ISO 13485 and ISO 22301 certified imaging core lab, announced today that it has been awarded a global Phase II clinical trial designed to investigate the safety and efficacy of a new pharmaceutical compound to treat Arthritis. According to the Arthritis Foundation, more than 50 million adults and 300,000 children have one of the more than 100 different types of arthritis and related conditions.

Intrinsic Imaging, an FDA audited, ISO 9001, ISO 13485 and ISO 22301 certified imaging core lab, announced today that it has been awarded a global Phase II clinical trial designed to investigate the safety and efficacy of a new pharmaceutical compound to treat Arthritis.

As an Imaging Core Lab, Intrinsic Imaging's team has extensive experience in providing services in support of Phase I-IV Clinical Trials and Medical Device Trials involving the Musculoskeletal System (MSK). Intrinsic Imaging’s MSK team consists of 12 full-time board-certified, fellowship trained radiologists all of whom have expertise in the full complement of joint and spine disease processes as well as musculoskeletal interventions including pain management and device.

Intrinsic Imaging has a wealth of experience in the imaging and qualitative evaluation of Arthritis as well as significant expertise in the quantitative assessments of certain types of Arthritis using Kellgren-Lawrence, OARSI, WORMS and MOCART scoring criteria.

Throughout this four-year international trial, which includes over 2,400 radiological evaluations, Intrinsic Imaging will provide comprehensive imaging core lab services including, but not limited to, protocol and charter development, site qualification, site training and management, image transfer and processing.

“The outcome of this Phase II study will determine if this new treatment compares favorably with the leading treatment for Arthritis,” said Todd A. Joron, President & COO at Intrinsic Imaging. “At Intrinsic Imaging, we are very proud to provide our expertise in assessing if this new treatment could bring renewed hope for those facing the difficult challenge of having Arthritis.”

According to the Arthritis Foundation, Arthritis is the leading cause of disability in America. In 2016, more than 50 million adults and 300,000 children have one of the more than 100 different types of Arthritis and related conditions.

About Intrinsic Imaging
Located in Bolton, Massachusetts and San Antonio, Texas, Intrinsic Imaging is an FDA audited, ISO 9001, 13485 and 22301 certified, medical imaging core lab specializing in providing imaging core lab services for clinical trials. With its team of more than sixty-five board-certified fellowship trained radiologists, robust and scalable clinical imaging technologies and our ISO certified and registered quality management systems, Intrinsic Imaging is ideally positioned to provide unprecedented imaging core lab services around the world.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Craig Pennington
@IntrinsicCRO
Follow >
Visit website